Eli Lilly to buy bowel disease drug developer Morphic for US$3.2-billion

Phase News

Eli Lilly to buy bowel disease drug developer Morphic for US$3.2-billion
JohnsonShareLilly
  • 📰 globeandmail
  • ⏱ Reading Time:
  • 17 sec. here
  • 12 min. at publisher
  • 📊 Quality Score:
  • News: 45%
  • Publisher: 92%

The acquisition gives Eli Lilly access to an experimental drug for types of inflammatory bowel diseases

for $3.2-billion in cash, the companies said on Monday, giving the U.S. drugmaker access to an experimental drug for types of inflammatory bowel diseases.

Morphic’s lead drug MORF-057 is an oral treatment that is being evaluated in two phase 2 studies in ulcerative colitis patients and one phase 2 study in Crohn’s disease. Last year, the U.S. Food and Drug Administration approved Lilly’s Omvoh for treating adults with moderate-to-severe active ulcerative colitis.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

globeandmail /  🏆 5. in CA

Johnson Share Lilly Drug Cent Study Colitis Lilly U.S. Food And Drug Administration Pfizer

Canada Latest News, Canada Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Lilly agrees to buy U.S. biotech Morphic in US$3.2 billion dealLilly agrees to buy U.S. biotech Morphic in US$3.2 billion dealEli Lilly & Co. agreed to buy U.S. biopharma company Morphic Holding Inc. for about US$3.2 billion to gain experimental therapies for inflammatory bowel disease and other chronic illnesses.
Read more »

Lilly Agrees to Buy US Biotech Morphic in $3.2 Billion DealLilly Agrees to Buy US Biotech Morphic in $3.2 Billion Deal(Bloomberg) -- Eli Lilly & Co. agreed to buy U.S. biopharma company Morphic Holding Inc. for about $3.2 billion to gain experimental therapies for...
Read more »

Eli Lilly exec on weight-loss drugs: 'It's not just a flash in the pan'Eli Lilly exec on weight-loss drugs: 'It's not just a flash in the pan'Eli Lilly may be riding high on its diabetes and weight-loss treatments Mounjaro and Zepbound — which Wall Street estimates could net the company $13.5...
Read more »

FDA panel votes unanimously for Eli Lilly's Alzheimer's treatmentFDA panel votes unanimously for Eli Lilly's Alzheimer's treatmentAn FDA panel voted unanimously to support Eli Lilly's Alzheimer's drug for use in adults 60-85 years old.
Read more »

FDA panel votes to recommend Eli Lilly's Alzheimer's drugFDA panel votes to recommend Eli Lilly's Alzheimer's drugA US Food and Drug Administration (FDA) panel voted unanimously 11-0 to recommend the approval of Eli Lilly's (LLY) Alzheimer's drug, donanemab. Yahoo...
Read more »

FDA approves Eli Lilly's Alzheimer's drug KisunlaFDA approves Eli Lilly's Alzheimer's drug KisunlaEli Lilly's (LLY) Alzheimer's treatment drug Kisunla has gained approval by the US Food and Drug Administration. Yahoo Finance Health Reporter Anjalee...
Read more »



Render Time: 2025-02-13 10:58:16